LakeShore Biopharma Co Net Tangible Assets

The latest net tangible assets for LSB is $500M as of March 2025. That compares with $590M in the prior-year period — down 14.6% year over year. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, LSB's net tangible assets moved from $590M to $500M — a 14.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co's operating scale or balance-sheet position.

A net tangible assets figure of $500M for LSB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LSB's net tangible assets ($500M), review year-over-year change from $590M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.